Home Products Most Popular Contact
No items in your cart.
The page below is a sample from the LabCE course Rh-Negative Female with Anti-D at Delivery: A Case Study (retired 6/11/2018). Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Rh-Negative Female with Anti-D at Delivery: A Case Study (retired 6/11/2018) (online CE course) »
How to Subscribe
Individual course$20 Add to cart

Screening for Fetomaternal Hemorrhage (FMH)

FMH greater than 30 mL of whole blood occurs in only about 0.3% of cases but must be detected to prevent the mother from producing anti-D. Once the mother has become immunized, it cannot be undone and RhIg is of no use.

A typical test protocol is first to screen for a large FMH and then quantitate the bleed if the screen is positive. Some laboratories proceed directly to a test that can quantitate the size of the FMH.

Once the size of the FMH is determined, a formula is used to determine how much RhIg is needed. Recall that:

  • A standard vial of RhIg contains 1500 IU (300 µg) of IgG anti-D;
  • 300 µg of RhIg can suppress immunization to approximately 30 mL of D-positive whole blood.

Several methods are available to detect FMHs that require additional RhIg.

Acceptable screening tests for FMH include

  • Rosette method;
  • Commercial fetal bleed screening tests;
  • Gel agglutination fetal cell screening technique.

NoteThe rosette test may be falsely positive if the mother is weak-D positive and may be falsely negative if the baby is weak-D positive.